We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genome Analysis Study to Aid Diagnosis of Rare Developmental Disorders

By LabMedica International staff writers
Posted on 06 Jan 2015
First results from a study that will eventually incorporate complete genome analysis of 12,000 families in the United Kingdom and the Republic of Ireland have revealed 12 novel genes associated with rare and difficult to diagnose developmental disorders.

The Deciphering Developmental Disorders (DDD) study, which is underwritten primarily by the Wellcome Trust Sanger Institute (Hinxton, United Kingdom) was designed to capitalize on the latest genetic techniques in order to help doctors understand the basis for developmental disorders. More...
The program has brought together clinicians in the 24 Regional Genetics Services throughout the United Kingdom and researchers at the Wellcome Trust Sanger Institute, which played a leading role in sequencing the human genome. The DDD study involves experts in clinical, molecular, and statistical genetics as well as in ethics and social science.

The first paper to be published under the auspices of the DDD program reported results from a study of 1,133 children with severe, undiagnosed developmental disorders, and their parents, using a combination of exome sequencing and array-based detection of chromosomal rearrangements. The investigators reported discovering 12 novel genes associated with developmental disorders. These newly implicated genes increased by 10% (from 28% to 31%) the proportion of children that could be diagnosed. All of the newly diagnosed developmental disorders were caused by de novo mutations, which were present in the child but not in their parents' genomes.

DDD's nationwide secure data-sharing network made it possible to find and compare these rare disorders. For example, for four of the 12 newly identified genes, identical mutations were found in two or more unrelated children living hundreds of miles apart. In another example, two unrelated children, both with identical mutations in the PCGF2 (Polycomb group RING finger protein 2) gene, which is involved in regulating genes important in embryo development, were found to have strikingly similar symptoms and facial features. This discovery enabled the certification of a new, distinct dysmorphic syndrome.

"The DDD study has shown how combining genetic sequencing with more traditional strategies for studying patients with very similar symptoms can enable large-scale gene discovery," said contributing author Dr. John Burn, professor of clinical genetics at Newcastle University (United Kingdom). "This data-set becomes more effective with each diagnosis and each newly identified gene."

The study was published in the December 24, 2014, online edition of the journal Nature.

Related Links:

Wellcome Trust Sanger Institute
Newcastle University



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.